Study identifier:D5360C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IIIb study to assess the efficacy, safety & Product attributes of Rhinocort Aqua(Budesonide) versus placebo and FluticasonePropionate as an active comparator in patients 12yrs age &older with SeasonalAllergicRhinitis
Seasonal Allergic Rhinitis
Phase 3
No
Budesonide, Fluticasone propionate, Placebo
All
750
Interventional
12 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Budesonide | - |
Active Comparator: 2 Fluticasone propionate | - |
Placebo Comparator: 3 | - |